QUOTE AND NEWS
Clusterstock  May 13  Comment 
By Greg Roumeliotis and Lauren Hirsch (Reuters) - France's Sanofi SA was moving ahead on Friday with preparations to replace Medivation Inc's board of directors after the U.S. cancer drug maker refused to engage with it in sale talks based on a...
FiercePharma  May 12  Comment 
Sanofi recalls painkiller in India epalmer Thu, 05/12/2016 - 10:07
The Hindu Business Line  May 12  Comment 
Benzinga  May 12  Comment 
Analysts at SunTrust Robinson Humphrey upgraded WebMD Health Corp. (NASDAQ: WBMD) from Neutral to Buy. WebMD Health shares fell 1.09 percent to close at $62.75 on Thursday. BMO Capital upgraded Silver Wheaton Corp. (USA) (NYSE: SLW) from...
Benzinga  May 12  Comment 
Sanofi SA (ADR) (NYSE: SNY) shares have lost 9 percent year-to-date, mainly on concerns related to diabetes and Praluent. Barclays’ Michael Leuchten upgraded the rating for the company from Equal-Weight to Overweight, while maintaining the price...
FiercePharma  May 11  Comment 
Cigna inks results-based deals on pricey Amgen, Sanofi PCSK9 meds tracystaton Wed, 05/11/2016 - 09:22
Benzinga  May 10  Comment 
Medivation Inc (NASDAQ: MDVN) had an offer on the table to be acquired by Sanofi SA (ADR) (NYSE: SNY) for $9.3 billion, or $52.50 per share. Medivation rejected Sanofi's buyout offer and argued that its own business plan and strategy will...
MedPage Today  May 9  Comment 
(MedPage Today) -- Prophylaxis lowered overall costs, study finds
Clusterstock  May 9  Comment 
By Greg Roumeliotis and Pamela Barbaglia (Reuters) - U.S. cancer drug maker Medivation Inc has decided to explore a sale following a $9.3 billion acquisition offer from France's Sanofi SA and interest from other companies, people familiar with...
FiercePharma  May 6  Comment 
Undeterred by hostile threats, Medivation spurns Sanofi again chelfand Fri, 05/06/2016 - 11:10
Benzinga  May 6  Comment 
Medivation Inc (NASDAQ: MDVN) reported its U.S. and ex-U.S. Xtandi sales for 1Q16 in line with the consensus. Brean Capital’s Jonathan Aschoff maintains a Buy rating on the company, with a price target of $61. Xtandi Outlook Growth in the...




Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki